To determine the efficacy and the safety of PREOB®, a proprietary population of autologous bone-forming cells, in the treatment of non-infected hypotrophic non-union fractures of long bones.
ID
Source
Brief title
Condition
- Fractures
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Clinical symptoms: global disease evaluation using a visual analogue scale;
radiological healing: Radiographic Union Scale for Tibial (RUST) Fracture
extended to all long bones fractures as assessed by CT scan.
Secondary outcome
Clinical symptoms:
- Pain et fracture site at rest, during activities, at palpation using a Usual
Analogue Scale
-Well-being Score (SF12v2)
- Weight-bearing score
Radiological healing: Radiographic Union Scale for Tibial (RUST) Fracture
exiended to all long bones fractures as assessed by conventional X-ray.
Background summary
Pseudoarthrosis is a bone disorder characterised by a failure of the fracture
to heal within 6 months after the fracture occured. The normal time for
fracture healing is about 3 months. Possible causes for pseudoarthrosis can be
poor fracture stabilisation or local infection. When these causes are excluded,
the reason for this impaired fracture healing seems to be a failure of specific
bone cells (called osteoblasts) to multiply. Currently, the most common
treatment involves surgery done under general anesthesia during which a piece
of bone is taken from the pelvis to be reimplanted directly at the site of the
pseudoarthrosis. This treatment also known as autologous bone graft generates
good results but requires major surgery of several hours under general
anesthesia, followed by about 4 to 5 days of hospitalisation.
Study objective
To determine the efficacy and the safety of PREOB®, a proprietary population of
autologous bone-forming cells, in the treatment of non-infected hypotrophic
non-union fractures of long bones.
Study design
The study will be performed over two years as a randomised, open, controlled
intervention study. A total of 176 patients
with non-infected hypotrophic non-union fractures of long bones will be
randomized into 2 study arms: 88 patients in the
PREOB group and 88 patients in the bone autograft surgery group. The study will
consist of maximum 9 visits and 4 follow-up phone calls.
Intervention
Study group: percutaneous injection of 2,3, or 4 ml PREOB® suspension
(depending on the fracture interline, at a concentration of 4 x 10E6 cells/ml)
using a 3 mm trephine into the fracture site.
Control group: bone autograft surgery following standard of care practices of
the centre.
Study burden and risks
- 9 blood samples
- 6 x SF-12 questionnaire (also 4x during follow-up period)
- 6 x X-ray of the fracture
- 5 x CT of the fracture
For participating women, a pregnancy test will be performed at each visit.
The burden associated with study participation, besides the standard
procedures, lay mainly with the bone marrow and blood sampling.
There is more consulting and medical imaging (X-ray and CT), besides extra lab
testing.
The questionnaires patients have to complete can also be seen as a burden.
Rue Auguste Piccard 37
Gosselies 6041
BE
Rue Auguste Piccard 37
Gosselies 6041
BE
Listed location countries
Age
Inclusion criteria
Men and women, aged between 18 and 65 years old
Diagnosed with non-infected hypotrophic non-union fractures as confirmed by X-ray
Exclusion criteria
Fracture interline > 1 cm
Open fracture with septic local infection
Insufficient fracture stability
Osteosynthesis material other than intramedullary nails, scews, plates or external fixation
Bone infection
Multifocal fracture / non-union
Non-union or non-consolidated fracture on the neighbouring bone
Nerve damages or tendon lesion at the non-union fracture site
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
EudraCT | EUCTR2011-005584-24-NL |
ClinicalTrials.gov | NCT01756326 |
CCMO | NL44005.000.13 |